Abbvie Inc (ABBV)

$259.36 +2.44 (0.95%)
Market Cap 458.24B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 25.21
Forward PE 18.12
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 4,195,400
Avg Vol 6,979,778
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 91%
Beta 0.30
Analysts Strong Sell
Price Target $264.93

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
MC_Official
MC_Official Jul. 27 at 2:44 AM
Watchlist! (27/07)💯 All-Time High Breakout: $ABBV 🩺 CALLS ABOVE $261.64 📈 $MRK 💊 CALLS ABOVE $134.63 📈 Inside Bar: (D) $PCG 🪫 CALLS ABOVE $17.99 📈 PUTS BELOW $17.46 📉 $SPCX 🪐 CALLS ABOVE $118.55 📈 PUTS BELOW $110.85 📉 Let’s see how these play out🚀
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 26 at 9:00 PM
$SLS $ABBV The most Direct Head to Head AML REMISSION CR1 Phase 3 TRIAL Comp for the SLS REGAL CONTROL ARM - VIALE-M - Will never Be Published. Because it FAILED -- VIALE-M PHASE 3 FAILED Aza+VEN Failed CR1 Maintenance just like VIALE-T FAILED Post Transplant Maintenance and the LDAC+VEN P3 ALSO FAILED. This is why Shorts are now COVERING BIG TIME ahead of the Imminently Due GPS Phase 3 Results. $CAPR
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 26 at 8:05 PM
$SLS $ABBV $20 - $25 on the 80th Event PR and climbing 10x+ $135 per share on the P3 Results. Gps is about to get a Fda green light to Generate Tens of Billions in Real Revenue - worth every nickel of $50B to $LLY Abbv PFE . * its Now Day 80 Since the 78th Event -- and we've been seeing an Event Every 22 Days ... B Holding. ABVX is a Great Example of the Massive Value associated with positive Phase 3 Registrational Results - ie trial results confirming approval and VALUE. From $5 and change to $148 - Based on P3 Data. Something very Similar will be Happening here - ANY DAY NOW.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 26 at 7:53 PM
$SLS $LLY $ABBV Just CR2/3 AML Remission Maintenance is worth more than $100 Per Share Once Topline Phase 3 Registratinal Results are IN, there will be No question Regarding GPS FDA APPROVAL - and Institutional Funds and Big Pharma will Sizing up this Valuation Model at that Moment. 10x to 27X ROI Incoming ... and it is Imminent. A good time to be Loading in... Phase 3 Results will give Gps the FDA Green Light to Generate Tens of Billions of dollars in Real revenue worth $50B to Big Pharma - and the 80th Event PR is Imminent. Updated July Cr2/3 TAM Analysis
0 · Reply
alphatrades09
alphatrades09 Jul. 26 at 7:07 PM
07/27/2026 Watchlist All-Time High Breakout $ABBV • Calls above $261.64 $MRK • Calls above $134.63 Inside Bar (D) $PCG • Calls above $17.99 • Puts below $17.46 $SPCX • Calls above $118.55 • Puts below $110.85 These are the key levels I’m watching based on my own analysis. Looking forward to tomorrow’s session.
0 · Reply
MicheleMarquis
MicheleMarquis Jul. 26 at 1:19 PM
$ZENA ZenaTech's Drone as a Service Closes 26th Acquisition of an Ohio-based Land Surveying Company Licensed in Four States https://finance.yahoo.com/technology/articles/zenatechs-drone-closes-26th-acquisition-113000524.html $ABBV
0 · Reply
clan
clan Jul. 26 at 1:07 PM
$MNKD $27 in '27 Over the next year and a half +, as Mannkind's revenues and profits grow and risk evaporates and pipeline produces and debt gets paid down and collaborations build, investors will load up and P/E will rise to levels unimaginable to most. For the good of all Mannkind ... and MNKD. #GAMechanger #inflectionpoint #blockbuster #collaborations 🤑 $SPY $ABBV $QQQ 👀 EPS x P/E = SP $0.12 x 125 = $15/sh $0.20 x 125 = $25/sh $0.36 x 125 = $45/sh
0 · Reply
StrongUptrends
StrongUptrends Jul. 26 at 12:56 PM
$ABBV
0 · Reply
BioTechHealthX
BioTechHealthX Jul. 26 at 12:09 PM
$AZN $ABBV $JNJ $LLY $MRK From blockbuster weight-loss drugs to breakthrough cancer treatments, these 5 medicine stocks stand out for strong earnings, powerful pipelines and attractive long-term growth potential. https://biotechhealthx.com/biotech-news/5-best-medicine-stocks-that-could-make-investors-100-richer/
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 26 at 4:43 AM
$SLS $ABBV for all the short lowlife -- Aza+VEN, BAT for the SLS CONTROL ARM patients - FAILED 3 Large Phase 3 Trials conducted by ABBV - it Failed the REGAL Control Patients As Well - only ignorant retail don't know. It is why SHORTS ARE IN COVER MODE --- Down 15% last report to the Lowest number of Short shares since March... Ahead of the IMMINENT 80th Event Announcement and Phase 3 Top Line Results --- SHORTS ARE COVERING ...
0 · Reply
Latest News on ABBV
Genmab, AbbVie provide clarification on Phase 3 EPCORE(R) DLBCL-1 trial

2026-07-23T20:05:43.000Z - 3 days ago

Genmab, AbbVie provide clarification on Phase 3 EPCORE(R) DLBCL-1 trial

GMAB

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jul 23, 2026, 4:00 PM EDT - 3 days ago

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

GMAB

AbbVie price target raised to $282 from $273 at Canaccord

2026-07-22T10:40:12.000Z - 4 days ago

AbbVie price target raised to $282 from $273 at Canaccord

AbbVie’s Allergan Aesthetics receives approval for Boey in Europe

2026-07-17T12:05:34.000Z - 9 days ago

AbbVie’s Allergan Aesthetics receives approval for Boey in Europe

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jul 17, 2026, 8:00 AM EDT - 9 days ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

AbbVie price target raised to $260 from $230 at Citi

2026-07-15T10:21:06.000Z - 11 days ago

AbbVie price target raised to $260 from $230 at Citi

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Jul 14, 2026, 8:05 AM EDT - 12 days ago

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Jul 13, 2026, 5:06 PM EDT - 13 days ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

APGE SBIO

AbbVie price target raised to $260 from $230 at UBS

2026-07-13T16:30:09.000Z - 13 days ago

AbbVie price target raised to $260 from $230 at UBS

AbbVie price target raised to $300 from $258 at BMO Capital

2026-07-13T12:27:09.000Z - 13 days ago

AbbVie price target raised to $300 from $258 at BMO Capital

2 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now for August Payouts

2026-07-10T23:36:54.000Z - 16 days ago

2 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now for August Payouts

ABT

AbbVie price target raised to $280 from $260 at RBC Capital

2026-07-10T13:10:21.000Z - 16 days ago

AbbVie price target raised to $280 from $260 at RBC Capital

AbbVie price target raised to $276 from $234 at BofA

2026-07-10T10:31:16.000Z - 16 days ago

AbbVie price target raised to $276 from $234 at BofA

AbbVie price target raised to $295 from $260 at Wells Fargo

2026-07-10T10:20:22.000Z - 16 days ago

AbbVie price target raised to $295 from $260 at Wells Fargo

AbbVie price target raised to $280 from $260 at JPMorgan

2026-07-09T12:06:14.000Z - 17 days ago

AbbVie price target raised to $280 from $260 at JPMorgan

AbbVie price target raised to $261 from $249 at Guggenheim

2026-07-09T11:30:42.000Z - 17 days ago

AbbVie price target raised to $261 from $249 at Guggenheim

Buy these quality, low-stress stocks for the summer, says Jefferies

Jul 7, 2026, 11:45 AM EDT - 19 days ago

Buy these quality, low-stress stocks for the summer, says Jefferies

AXP HD LOW MCD NFLX PEP PG

AbbVie says Q2 EPS to include unfavorable impact of 17c

2026-07-06T20:20:39.000Z - 20 days ago

AbbVie says Q2 EPS to include unfavorable impact of 17c

AbbVie sees Q2 adjusted EPS ex-items $3.57-$3.61, consensus $3.77

2026-07-06T20:20:19.000Z - 20 days ago

AbbVie sees Q2 adjusted EPS ex-items $3.57-$3.61, consensus $3.77

AbbVie cuts FY26 adjusted EPS view to $13.91-$14.11 from $14.08-$14.28

2026-07-06T20:20:13.000Z - 20 days ago

AbbVie cuts FY26 adjusted EPS view to $13.91-$14.11 from $14.08-$14.28

AbbVie says Tepkinly combo approved by EC for lymphoma treatment

2026-07-06T17:50:14.000Z - 20 days ago

AbbVie says Tepkinly combo approved by EC for lymphoma treatment

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Jul 6, 2026, 1:45 PM EDT - 20 days ago

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

US House committee opens investigation into Merck, AbbVie China drug trials

Jun 30, 2026, 6:02 AM EDT - 26 days ago

US House committee opens investigation into Merck, AbbVie China drug trials

MRK

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jun 29, 2026, 4:15 PM EDT - 27 days ago

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jun 29, 2026, 3:10 AM EDT - 4 weeks ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

Jun 29, 2026, 3:00 AM EDT - 4 weeks ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Jun 26, 2026, 4:50 PM EDT - 4 weeks ago

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 4 weeks ago

Healthcare stocks have become a haven for investors ditching tech

ABSI APGE JNJ LLY MRNA SNY XBI

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 4 weeks ago

AbbVie's $11 Billion Immunology Bet

APGE

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Jun 24, 2026, 8:00 AM EDT - 4 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jun 23, 2026, 8:00 AM EDT - 4 weeks ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 5:00 AM EDT - 4 weeks ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Jun 23, 2026, 3:00 AM EDT - 4 weeks ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

EC

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

Jun 22, 2026, 10:30 AM EDT - 4 weeks ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 4 weeks ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Transcript: M&A announcement

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Slides: M&A announcement

AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Press release: M&A announcement

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 4 weeks ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

Jun 22, 2026, 7:06 AM EDT - 4 weeks ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 4 weeks ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

Jun 22, 2026, 7:00 AM EDT - 4 weeks ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

AbbVie would gain an experimental eczema drug by buying biotech: report

Jun 20, 2026, 12:11 PM EDT - 5 weeks ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

Jun 19, 2026, 11:17 AM EDT - 5 weeks ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 5 weeks ago

AbbVie Declares Quarterly Dividend

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 16, 2026, 8:00 AM EDT - 5 weeks ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 12, 2026, 3:00 AM EDT - 6 weeks ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 6 weeks ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ALKS AMGN GILD IBB IHE JNJ KYMR

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 10, 2026, 11:47 AM EDT - 6 weeks ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:40 AM EDT - 6 weeks ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 8, 2026, 8:00 AM EDT - 6 weeks ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 7:04 PM EDT - 7 weeks ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Jun 3, 2026, 3:30 AM EDT - 7 weeks ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 2, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 29, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 6:18 PM EDT - 2 months ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 2 months ago

US FDA approves AbbVie's rare blood cancer drug

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 22, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 6:46 PM EDT - 2 months ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 21, 2026, 4:10 PM EDT - 2 months ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 2 months ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 2 months ago

AbbVie Transcript: AGM 2026

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 6, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

May 5, 2026, 8:05 AM EDT - 2 months ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 3:05 PM EDT - 3 months ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 3 months ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 3:00 PM EDT - 3 months ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 30, 2026, 9:00 AM EDT - 3 months ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 3 months ago

AbbVie Earnings Call Transcript: Q1 2026

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 3 months ago

AbbVie Earnings release: Q1 2026

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 3 months ago

AbbVie Quarterly report: Q1 2026

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 3 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:50 AM EDT - 3 months ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

MC_Official
MC_Official Jul. 27 at 2:44 AM
Watchlist! (27/07)💯 All-Time High Breakout: $ABBV 🩺 CALLS ABOVE $261.64 📈 $MRK 💊 CALLS ABOVE $134.63 📈 Inside Bar: (D) $PCG 🪫 CALLS ABOVE $17.99 📈 PUTS BELOW $17.46 📉 $SPCX 🪐 CALLS ABOVE $118.55 📈 PUTS BELOW $110.85 📉 Let’s see how these play out🚀
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 26 at 9:00 PM
$SLS $ABBV The most Direct Head to Head AML REMISSION CR1 Phase 3 TRIAL Comp for the SLS REGAL CONTROL ARM - VIALE-M - Will never Be Published. Because it FAILED -- VIALE-M PHASE 3 FAILED Aza+VEN Failed CR1 Maintenance just like VIALE-T FAILED Post Transplant Maintenance and the LDAC+VEN P3 ALSO FAILED. This is why Shorts are now COVERING BIG TIME ahead of the Imminently Due GPS Phase 3 Results. $CAPR
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 26 at 8:05 PM
$SLS $ABBV $20 - $25 on the 80th Event PR and climbing 10x+ $135 per share on the P3 Results. Gps is about to get a Fda green light to Generate Tens of Billions in Real Revenue - worth every nickel of $50B to $LLY Abbv PFE . * its Now Day 80 Since the 78th Event -- and we've been seeing an Event Every 22 Days ... B Holding. ABVX is a Great Example of the Massive Value associated with positive Phase 3 Registrational Results - ie trial results confirming approval and VALUE. From $5 and change to $148 - Based on P3 Data. Something very Similar will be Happening here - ANY DAY NOW.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 26 at 7:53 PM
$SLS $LLY $ABBV Just CR2/3 AML Remission Maintenance is worth more than $100 Per Share Once Topline Phase 3 Registratinal Results are IN, there will be No question Regarding GPS FDA APPROVAL - and Institutional Funds and Big Pharma will Sizing up this Valuation Model at that Moment. 10x to 27X ROI Incoming ... and it is Imminent. A good time to be Loading in... Phase 3 Results will give Gps the FDA Green Light to Generate Tens of Billions of dollars in Real revenue worth $50B to Big Pharma - and the 80th Event PR is Imminent. Updated July Cr2/3 TAM Analysis
0 · Reply
alphatrades09
alphatrades09 Jul. 26 at 7:07 PM
07/27/2026 Watchlist All-Time High Breakout $ABBV • Calls above $261.64 $MRK • Calls above $134.63 Inside Bar (D) $PCG • Calls above $17.99 • Puts below $17.46 $SPCX • Calls above $118.55 • Puts below $110.85 These are the key levels I’m watching based on my own analysis. Looking forward to tomorrow’s session.
0 · Reply
MicheleMarquis
MicheleMarquis Jul. 26 at 1:19 PM
$ZENA ZenaTech's Drone as a Service Closes 26th Acquisition of an Ohio-based Land Surveying Company Licensed in Four States https://finance.yahoo.com/technology/articles/zenatechs-drone-closes-26th-acquisition-113000524.html $ABBV
0 · Reply
clan
clan Jul. 26 at 1:07 PM
$MNKD $27 in '27 Over the next year and a half +, as Mannkind's revenues and profits grow and risk evaporates and pipeline produces and debt gets paid down and collaborations build, investors will load up and P/E will rise to levels unimaginable to most. For the good of all Mannkind ... and MNKD. #GAMechanger #inflectionpoint #blockbuster #collaborations 🤑 $SPY $ABBV $QQQ 👀 EPS x P/E = SP $0.12 x 125 = $15/sh $0.20 x 125 = $25/sh $0.36 x 125 = $45/sh
0 · Reply
StrongUptrends
StrongUptrends Jul. 26 at 12:56 PM
$ABBV
0 · Reply
BioTechHealthX
BioTechHealthX Jul. 26 at 12:09 PM
$AZN $ABBV $JNJ $LLY $MRK From blockbuster weight-loss drugs to breakthrough cancer treatments, these 5 medicine stocks stand out for strong earnings, powerful pipelines and attractive long-term growth potential. https://biotechhealthx.com/biotech-news/5-best-medicine-stocks-that-could-make-investors-100-richer/
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 26 at 4:43 AM
$SLS $ABBV for all the short lowlife -- Aza+VEN, BAT for the SLS CONTROL ARM patients - FAILED 3 Large Phase 3 Trials conducted by ABBV - it Failed the REGAL Control Patients As Well - only ignorant retail don't know. It is why SHORTS ARE IN COVER MODE --- Down 15% last report to the Lowest number of Short shares since March... Ahead of the IMMINENT 80th Event Announcement and Phase 3 Top Line Results --- SHORTS ARE COVERING ...
0 · Reply
Stocks_Spot
Stocks_Spot Jul. 25 at 4:49 PM
$ABBV is approaching a key catalyst: Q2 earnings on July 31. The main question is whether Skyrizi and Rinvoq can maintain strong growth and continue to more than offset Humira’s decline. In Q1, Skyrizi and Rinvoq sales rose 30.9% and 23.3%, respectively, prompting AbbVie to raise its 2026 earnings outlook. Expectations are therefore high, especially with the stock trading near its recent high. $JNJ also matters because Tremfya competes directly with Skyrizi in immunology. Strong JNJ growth could renew concerns about market-share pressure. My focus: Skyrizi/Rinvoq sales, guidance and competitive pressure. Not financial advice. Do your own research.
0 · Reply
liteprofitl_b
liteprofitl_b Jul. 25 at 4:17 PM
Let's print next week. 💰 Haven't joined the moving train yet? The link's in my bio. ⚡️ $AAPL $ARM $ABBV $BA
0 · Reply
Tom2772
Tom2772 Jul. 25 at 6:04 AM
$OTLK $ABBV $JNJ 🇺🇸🇪🇺 U.S. & European Expansion | Commercial Launch 🚀 🇺🇸 United States: FDA approved. First and only FDA-approved ophthalmic bevacizumab for wet AMD. Entering an estimated $8.5B annual U.S. anti-VEGF retina market with an expected 12 years of regulatory exclusivity. Commercial launch with Cencora expected before year-end. 🇪🇺 European Union: Approved by the European Commission – commercial rollout underway. 🇬🇧 United Kingdom: MHRA approved – commercially available. 🇩🇪 Germany: Commercially available. 🇦🇹 Austria: Commercially available. 🇳🇱 Netherlands & 🇮🇪 Ireland: Target launch in 2026. 🇫🇷 France, 🇮🇹 Italy & 🇪🇸 Spain: Target launch in 2027. 🇨🇭 Switzerland: Exclusive partnership with Mediconsult AG. Outlook is expanding its commercial organization ahead of the U.S. launch. The FDA approval removed the biggest hurdle. Know what you own! 💎
0 · Reply
Scanlz
Scanlz Jul. 24 at 8:24 PM
I'm lucky I pick it up around the $90 value 😁 $ABBV
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 24 at 6:32 PM
$MRNA $ABBV $COR $ABC
0 · Reply
GoforProMIS
GoforProMIS Jul. 24 at 2:35 PM
$PMN might the new Sherrif in town for Alzheimer Disease and several other neurological disorders $MRK $ABBV $AMGN
0 · Reply
JFDI
JFDI Jul. 24 at 1:42 PM
$ABBV continuation potnetial.
0 · Reply
DefenseMania
DefenseMania Jul. 24 at 1:34 PM
$ABBV $AMGN DRIPPING these for over 9 years , closing in on 52wk highs 💰💰💰 also hold $PFE $GILD EXEL
0 · Reply
Jinxis
Jinxis Jul. 23 at 6:49 PM
$SPY Days like today, it can be worth noting whats still green $ABBV $JNJ $BMY 👀
0 · Reply
VeltrixCapitalOfficial
VeltrixCapitalOfficial Jul. 23 at 3:29 PM
$ABBV $ABBV @.25 | +120% 🔥🔥🔥 SOLD MOST , LEFT RUNNERS
0 · Reply
VeltrixCapitalOfficial
VeltrixCapitalOfficial Jul. 23 at 2:47 PM
$ABBV @.18 | +60% 🔥🔥🔥 SOLD MOST , LEFT RUNNERS TURN MY NOTIFICAITONS ON
0 · Reply
liamsniperalert
liamsniperalert Jul. 23 at 2:16 PM
7/24 $ABBV 265c @​ .13
0 · Reply